Monash IVF's Takeover Appeal Remains -- Market Talk

Dow Jones

01/14

2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. "We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time," analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 13, 2026 16:56 ET (21:56 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603536996"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603536996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603536996?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603536996","market":"sg","top_or_hot":-1,"title":"Monash IVF's Takeover Appeal Remains -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monash IVF's Takeover Appeal Remains -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonash IVF's Takeover Appeal Remains -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 05:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including <a href=\"https://laohu8.com/S/SOL.AU\">Washington H. Soul Pattinson</a>, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVF","symbol_name":"INVO Fertility, Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603536996","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603536996","pubTimestamp":1768341360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVF":"INVO Fertility, Inc","MVF.AU":"MONASH IVF GROUP LTD","BK7113":"保健护理机构","BK4082":"医疗保健设备","BK7508":"医药生物股"},"translate_title":"莫纳什IVF的收购吸引力依然存在——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVF":1.5,"MVF.AU":0.9},"content_text":"2156 GMT - In vitro fertilization specialist Monash IVF may no longer be a bid target of a group including Washington H. Soul Pattinson, but Jefferies thinks its takeover appeal remains. Monash IVF last month said Soul Patts and Genesis Capital Investment Management had withdrawn their A$0.80/share offer. \"We continue to believe that Monash IVF is a potentially attractive asset, and would not be surprised to see further potential corporate actions over time,\" analyst David Stanton says. Private equity has previously been interested in IVF specialists. Jefferies says that reflects the industry's high barriers to entry and supportive demographics. IVF is also a high cash flow business. Jefferies raises its price target on Monash IVF by 19% to A$0.95/share. Monash IVF ended Tuesday at A$0.745. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}